NASDAQ: TARSTarsus Pharmaceuticals Inc Stock
$32.76-0.95 (-2.82%)
Updated Apr 24, 2024
TARS Price
$32.76
Fair Value Price
$6.43
Market Cap
$1.12B
52 Week Low
$12.57
52 Week High
$40.40
P/E
-7.09x
P/B
5.69x
P/S
34.1x
PEG
N/A
Dividend Yield
N/A
Revenue
$17.45M
Earnings
-$135.89M
Gross Margin
90.9%
Operating Margin
-759.71%
Profit Margin
-778.9%
Debt to Equity
0.35
Operating Cash Flow
-$117M
Beta
1.01
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TARS Overview
Tarsus Pharmaceuticals Incorporated is a clinical-stage biopharmaceutical company that develops and commercializes ophthalmic and other therapies. The company's lead product candidate is TP-03, in a Phase III clinical trial, for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals was incorporated in 2016 and is headquartered in Irvine, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TARS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TARS ($32.76) is overvalued by 409.77% relative to our estimate of its Fair Value price of $6.43 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TARS ($32.76) is not significantly undervalued (409.77%) relative to our estimate of its Fair Value price of $6.43 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TARS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TARS due diligence checks available for Premium users.
Be the first to know about important TARS news, forecast changes, insider trades & much more!
TARS News
Valuation
TARS fair value
Fair Value of TARS stock based on Discounted Cash Flow (DCF)
Price
$32.76
Fair Value
$6.43
Overvalued by
409.77%
TARS ($32.76) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TARS ($32.76) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TARS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TARS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.09x
Industry
15.69x
Market
41.27x
TARS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.69x
Industry
5.86x
TARS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TARS's financial health
Profit margin
Revenue
$13.1M
Net Income
-$41.9M
Profit Margin
-320.4%
TARS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TARS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$265.5M
Liabilities
$68.5M
Debt to equity
0.35
TARS's short-term assets ($256.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TARS's short-term assets ($256.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TARS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TARS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$39.3M
Investing
$17.9M
Financing
$19.8M
TARS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TARS vs Biotech Stocks
Tarsus Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.